Nu Skin Enterprises Inc. expects China’s investigation of its business to temper its sales growth during and possibly beyond the current quarter, but the firm remains optimistic about its long-term prospects in the key market after reporting global full-year revenue growth of 49% in 2013.
China Regulatory Probe Slows Nu Skin Growth After Record Year
The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.
More from China
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.
US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.
More from Asia
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.